secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001193125-25-173033
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q2 rev $38.1M (+132% YoY); secures $10M additional debt; lowers liquidity requirement to $2M through Sep'26
--------------------------------------------------------------------------------

- Q2 2025 revenue $38.1M, up 132% YoY; adjusted pro forma growth 18%; net loss $(9.8)M ($0.15 loss per share).
- Record Greenbrook clinic revenue $23.0M; U.S. treatment session revenue $10.8M (pro forma +13%); shipped 41 NeuroStar systems.
- Received $10M Tranche 2A loan from Perceptive on Aug 1, 2025; minimum liquidity lowered to $2M through Sep 2026; still eligible for $5M more.
- Appointed Steven Pfanstiel as CFO effective July 15, 2025; succeeded Stephen Furlong.
- Guidance: Q3 rev $37-39M, FY rev $149-155M; FY operating expenses raised to $100-105M; cash flow positive expected in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312525173033/0001193125-25-173033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312525173033/d72601d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-173033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer